The mouse embryonic stem cell test (EST) is a 10-day screen for teratogenic potential developed to reduce animal use for embryotoxicity testing of chemicals (Spielmann, 2005; Spielmann et al., 1997). In this study, we used the cytotoxicity IC 50 values and transcriptional expression changes as primary endpoints in a shorter 4-day version of the EST, the molecular embryonic stem cell assay. Mouse D3 embryonic stem cells were used for cytotoxicity assessment (monolayers) or grown as embryoid bodies in low attachment plates for transcriptional profiling. Sixty-five compounds with known in vivo teratogenicity (33 teratogens and 32 nonteratogens) were evaluated to develop a model for classifying compounds with teratogenic potential. The expression of 12 developmentally regulated gene targets (nanog, fgf5, gsc, cd34, axin2, apln, chst7, lhx1, fgf8, sox17, foxa2, and cxcr4) was measured following exposure of embryoid bodies to a single compound concentration (0.1 × the cytotoxicity IC 20 ) for 4 days. In the decision-tree model, compounds with IC 50 values < 22µM were categorized as teratogens, whereas compounds in the two groups with IC 50 values between 22-200µM and > 200µM were categorized as teratogens if ≥ 8 and 12 genes, respectively, were deregulated by at least 10%. Fortyseven of 65 compounds of the training set were correctly identified (72% total concordance). In a test set of 12 additional compounds (5 teratogens, 7 nonteratogens), 10 were correctly classified by this approach (83% concordance). The false positive rate in the training and test sets was 24 and 0%, respectively, indicating that this assay has potential to identify teratogens.
We describe herein the molecular embryonic stem cell assay (MESCA) for high-throughput screening of xenobiotics for teratogenic potential. For exploratory pharmaceutical compounds, MESCA provides an initial evaluation, supporting lead selection and/or structure activity relationship analysis. The report describes two phases of assay development: (1) endpoint identification and assay optimization, and (2) development of a decision-tree classification process that best identifies teratogens and nonteratogens.
D3 embryonic stem (ES) cells originate from the inner cell mass of the mouse preimplantation embryo. Pluripotency is maintained in the presence of leukemia inhibitory factor (LIF). Under optimal growth conditions in the absence of LIF, D3 cells are capable of differentiation into lineages associated with all three germ layers: ectoderm, endoderm, and mesoderm. Early embryonic differentiation is promoted by aggregating cells into clusters called embryoid bodies (EBs), which are capable of differentiating into a variety of cell types.
Using the embryonic stem cell test (EST), the European Centre for Validation of Alternative Methods (ECVAM) correctly identified 78% of teratogens and nonteratogens Scholz et al., 1999) . The assay was developed to comply with REACH legislation (European Commission Regulation of Chemicals) that requires the reduction of animal use for embryotoxicity testing of chemicals (Spielmann, 2005; Spielmann et al., 1997) .
The EST classifies compounds for embryotoxicity potential by an algorithm that combines the extent of differentiation of mouse D3 cells with the degree of cytotoxicity observed in D3 cells and 3T3 fibroblasts. Three endpoints are required: the compound concentration producing 50% growth inhibition in D3 cells (IC 50 ES) and 3T3 cells (IC 50 3T3) and the compound concentration producing 50% inhibition of cardiomyocyte differentiation in D3 cells (ID 50 ES) Scholz et al., 1999; Spielmann et al., 1997) . Inhibition of differentiation at lower concentrations than those inducing cytotoxicity in either cell line is understood to be indicative of potential for selective embryotoxicity. Although the assay does not require the use of animals for embryotoxicity testing, it involves several laborious manipulations (hanging drop culture to produce EBs, transfer of individual EBs to individual wells, and visual assessment of cardiomyocyte differentiation) over 10 days that reduce throughput. Other drawbacks include the requirement of two cell lines tested over a range of concentrations to obtain IC 50 values.
Optimizing the EST assay design to increase overall throughput has been a common goal (Barrier et al., 2011; Bigot et al., 1999; Buesen et al., 2004; Peters et al., 2008; Seiler et al., 2002 Seiler et al., , 2004 Suzuki et al., 2011; van Dartel et al., 2009; zur Nieden et al., 2001 zur Nieden et al., , 2004 . Some advances include the development of an adherent ES assay (Barrier et al., 2011) or use of low-binding 96-well plates to eliminate the need for hanging drop cultures (Peters et al., 2008) . Alternative cardiomyocyte scoring methods have also been developed (Peters et al., 2008) . Several laboratories identified promising molecular endpoints (using RT-PCR, microarray, or flow cytometry) (Barrier et al., 2011; Bigot et al., 1999; Buesen et al., 2009; Romero et al., 2011; Seiler et al., 2002 Seiler et al., , 2004 van Dartel et al., 2009 van Dartel et al., , 2010a van Dartel et al., and b, 2011 zur Nieden et al., 2001 zur Nieden et al., , 2004 . Others used transgenic ES cells with reporter constructs to measure dose-dependent inhibition of genes normally expressed in cells undergoing differentiation (Suzuki et al., 2011) . None of these refinements led to an assay of reduced complexity that is significantly shorter than 10 days. Developing a simpler, faster assay was the primary objective for MESCA.
In many publications describing refinements to the EST, small numbers of compound were used for assay validation; test sets of less than 25 compounds with low representation of nonteratogens (< 9) were evaluated, limiting an accurate estimate of the false positive error rate associated with the selected endpoints (Barrier et al., 2011; Bigot et al., 1999; Buesen et al., 2004; Peters et al., 2008; Romero et al., 2011; Seiler et al., 2002 Seiler et al., , 2004 Suzuki et al., 2011; van Dartel et al., 2009 van Dartel et al., , 2010a van Dartel et al., and b, 2011 zur Nieden et al., 2001 zur Nieden et al., , 2004 . We recognized the need for a more extensive validation to establish better concordance.
MaTErIalS anD METhoDS
All methods and materials associated with phase I can be found in supplemental materials.
Test Chemicals
Seventy-seven structurally diverse compounds were selected for test optimization and validation (Tables 1 and 2 ). Thirty-eight compounds were categorized as teratogens and 39 compounds as nonteratogens based on published in vivo data summarized in the Catalog of Teratogenic Agents (Shepard and Lemire, 2007) and propriety data. Compounds were categorized as teratogens if they induced morphological abnormalities at doses that were less than or equal to those that caused minimal-to-mild maternal toxicity in at least one species. Compounds were categorized as nonteratogens if no structural malformations were observed in at least two species despite the presence of maternal toxicity. Compounds were purchased from Sigma-Aldrich (St Louis, MO) unless stated otherwise or synthesized at Bristol-Myers Squibb. In vivo findings, compound class, and teratogenic categorization are summarized in Tables  1 and 2 . Suppliers' catalog numbers for each compound are summarized in Supplementary table 1.
Cell Culture
D3 mouse ES cells (ATCC, Manassas, VA) were routinely passaged every 48-72 h at a density of 3 × 10 5 − 5 × 10 4 cells/ml with Dulbecco's Modified Eagle's Medium (Invitrogen, Carlsbad, CA), supplemented with 20% heat inactivated fetal bovine serum (Hyclone Laboratories Inc., Logan, UT), 2mM glutamine, 50 U/ml penicillin/strep, 1% nonessential amino acids (Invitrogen), and 0.1mM β-mercaptoethanol (Sigma-Aldrich). The LIF (Millipore, Billerica, MA) was added to the medium at a concentration of 1000 U/ml each time the cells were passaged to maintain pluripotency.
Viability Assay
Six-thousand cells/well were seeded in 96-well plates and incubated at 37°C and 5% CO 2 . Two hours later, the cells were exposed to test compound for 3 days at 37°C and 5% CO 2 . 3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium was used to assess cell viability following the manufacturer's recommendations (Promega, Madison, WI). Cytotoxicity was measured over eight serial dilutions of the test compound, with the highest concentration being the maximum soluble concentration. The IC 50 and IC 20 values were calculated from the concentration-response curves. The IC 50 values were used in the decision-tree process for identifying teratogens. The IC 20 values were used to establish the concentration used in the D3 differentiation assay. If these values could not be calculated from the initial experiment, concentrations and dilution factors were adjusted accordingly, and the experiment was repeated. Final viability assay compound concentrations are summarized in Supplementary table 2. Curves were replicated in triplicate. 
Differentiation Assay Compound Concentration Selection

Cell Differentiation Assay
Ninety-six-well low attachment plates. Compound treatment was performed as previously published Scholz et al., 1999; Spielmann et al., 1997) . Low attachment plates were hydrated following the manufacturer's recommendations (Corning, Corning, NY). To initiate EB differentiation, 750 cells/well were seeded with untreated or compound-treated medium in the inner 60 wells of a 96-well low attachment plate and incubated at 37°C and 5% CO 2 for 4 days.
EB collection. The EBs were collected in 600 µl RLT buffer (Qiagen, Valencia, CA) on day 4 and were homogenized with a 20 gauge needle and snap frozen. Samples were stored at −70°C until further analysis. Experiments were repeated in triplicate. 
cDNA Synthesis and RT-PCR
RNA was reverse transcribed into cDNA by random primers using the TaqMan High Capacity cDNA Archive Kit (Applied Biosystems, Carlsbad, CA). RT-PCR reactions were carried out in TaqMan low-density arrays preloaded with primer/ probe sets (designed and validated by Applied Biosystems, Carlsbad, CA) for genes of interest using an ABI 7900HT Sequence Detection System equipped with SDS v2.3 software. Each port was loaded with approximately 50 ng of cDNA. Cyclophillin B (ppib) was selected as an appropriate housekeeping gene for normalization in these experiments because a small variability in Ct values was observed between compound-treated and control samples and/or through time (data not shown). TaqMan primer/probe sets were purchased from Applied Biosystems and are listed in Supplementary table 3. The data were analyzed with the ∆Ct method following the manufacturer's instructions (Applied Biosystems, Carlsbad, CA). The vehicle control sample for each experiment was used as the calibrator. Mean relative quantitation (RQ) values were used for data interpretation.
Statistical Analysis
Comparison between MESCA and EST assay concordance. Fisher's exact test was used to identify any statistically significant (p ≤ 0.05) differences between the EST and MESCA assays with SAS software.
rESulTS
The evaluation was completed in two phases. In phase I, a series of experiments were conducted to select 12 potential molecular endpoints (apln, nanog, gsc, fgf5, cd34, lhx-1, fgf8, sox17, foxa2, cxcr4, chst7, and axin2) (Table 3) , as well as a single time point (day 4) to shorten the assay based on the expression profiles of the selected genes and the elimination of two labor-intensive steps in the EST and a single compound concentration (0.1 × IC 20 ) to include in the optimized assay. Also, transcriptional comparison of the genes and assay conditions selected in these experiments between the EBs generated by hanging drops versus low attachment plates ensured the possibility of assay automation (see Supplemental Materials for phase I methods and results). Phase II focused on building a teratogenicity classification model based upon transcriptional response data from 65 compounds using the conditions optimized in phase I. The performance of the model was further tested with 12 additional compounds.
Preliminary Testing of Optimized Conditions and Molecular Endpoints
Prior to initiating the large study, a preliminary experiment testing 5 in vivo teratogens and 5 nonteratogens was undertaken as a means to determine whether the time point (day 4), compound concentration (0.1 × IC 20 ), and 12 prioritized genes (Table 3 ) selected were sufficiently concordant to be used in model building for teratogenic classification.
Total percent concordance was calculated as in phase I. A 10% relative gene expression change was used to delineate between teratogens and nonteratogens (for each gene, ≤ 10% change in expression categorized a compound as a nonteratogen and a > 10% change in expression categorized a compound as a teratogen). Using this approach, if more than half the genes were affected, a compound was classified as positive for teratogenic potential. The percent of correctly identified teratogens and nonteratogens was 70% using the optimized assay conditions (Table 4) .
Model Building With 65 Compounds
The selected compounds are summarized in Table 1 . Initially, total concordance was calculated as described in the previous section using only gene expression data; however, Notes. Values represent relative gene expression (RQ) changes from the vehicle control. Shaded values represent correct classification of compounds by that specific gene (if more than 10% deregulation, the compound is categorized as a teratogen). If more than half the genes classified a compound as a teratogen, then the compound was classified as a teratogen. T, teratogen; NT, nonteratogen; DMP, dimethyl phthalate; DPH, diphenylhydantoin; ATRA, all-trans retinoic acid. In order to identify the best discriminators, all independent endpoint data values were sorted with Microsoft Excel (low to high) against in vivo teratogenic classification to determine whether there were any specific endpoints that were better at separating teratogens from nonteratogens. The first round of sorting identified the IC 50 as the best predictor because it was the only endpoint that was able to separate a third (11 of 33) of the teratogens from the nonteratogens without misclassifying any negative compounds. Because the IC 50 was the best discriminator in the first sorting attempt, the compounds correctly identified by this step (IC 50 < 22µM) were removed from the rest of the analysis. The > 10% gene deregulation approach utilized in phase I of this study was applied to the remaining transcriptional data (5-40% gene deregulation was also empirically attempted but produced suboptimal separation, data not shown). However, by sorting this data set by the IC 50 again, it was observed that teratogens with IC 50 values between 22 and 200µM were correctly identified if more than eight genes were deregulated by > 10%. At this point, it seemed appropriate to separate the compounds with IC 50 values greater than 22µM but less than 200µM from compounds that had IC 50 values greater than 200µM. By making this separation, most of the nonteratogens fell in the IC 50 > 200µM category, and a few of the teratogens in this category had all genes affected, further delineating the positive and negative compounds. Therefore, the IC 50 value calculated from the 3-day cytotoxicity curve is used in the first two steps of the classification approach.
Cytotoxicity
The range of cytotoxicity IC 50 values across all 65 compounds was 0.002 to > 10,000µM. Eleven of 33 teratogens had IC 50 values less than 22µM. None of the 32 nonteratogens had IC 50 values less than 22µM (Supplementary table 21) .
Changes in Gene Expression
The 10% change (±) in gene expression from control approach identified as optimal in phase I studies was used to classify compounds as teratogens. Eight of 9 teratogens with cytotoxicity IC 50 values greater than 22µM but less than 200µM increased or reduced the expression of at least 8 of the selected genes. Two of 13 teratogens with IC 50 values greater than 200µM changed gene expression in all 12 genes; however, 7 of these 13 teratogens had limited solubility, and an IC 20 concentration could not be established. Twenty-four of the 27 nonteratogens with IC 50 values greater than 200µM had changed gene expression in less than 12 genes (Fig. 1) .
Based on these results, the compounds' teratogenic classification was determined from the following approach: if the IC 50 is less than 22µM, then the compound will be classified as a teratogen. If the IC 50 is greater than 22µM, the compound will be tested at 0.1 × IC 20 in differentiating EBs. On day 4 of differentiation, the EBs are processed for mRNA and evaluated. For compounds with IC 50 values between 23-200µM, a > 10% change in gene expression for ≥ 8 genes of the 12-gene panel will classify a compound as a teratogen. If the IC 50 is greater than 200µM, then a > 10% change (±) in transcriptional expression for all 12 genes will classify a compound as a teratogen.
To make the assay robust (or resistant) to interexperimental variability, each biological replicate was generated with different lots of ES cells and at different cell passages. This means that the classification approach was built with 2535 data points (expression data from 12 genes and IC 50 values for 65 compounds in triplicates). The most frequent teratogenicity classification from the three biological replicates then determined the final compound classification. For example, if two of the three replicates classified a compound as a teratogen, then the compound was classified as positive for teratogenic potential.
Training set data and compound classifications are summarized in Supplementary table 21 and Table 5 . The teratogenicity classification approach is illustrated in Figure 1 , and the concordance and predictivity results are summarized in Table 5 . Based on the training set, the assay's sensitivity is 67% and the specificity is 78%. For teratogenic predictions of unknowns, the concordance for teratogens is 76% (22 out of 29), and for nonteratogens is 69% (25 out of 36) with a total concordance of 72% (47 out of 65). The false positive and negative error rates are 24 and 31%, respectively (Table 5) .
Model Testing With 12 Compounds
Twelve additional compounds with known in vivo teratogenicity were used to test the classification approach in a separate experiment ( Table 2 ). The classification approach was able to correctly classify 10 of the 12 compounds. Test set compound classification and data are summarized in Supplementary table 22 and Table 6 . Test set concordance is summarized in Table 6 . Based on the test set, the assay's sensitivity is 60% and the specificity is 100%. For teratogenic predictions of unknowns, the concordance for teratogens is 100% (3 out of 3), and for nonteratogens is 78% (7 out of 9) with a total concordance of 83% (10 out of 12). The false positive and negative error rates are 0 and 22%, respectively (Table 6 ).
Criteria to Manage Assay Interexperimental Variability
We learned that the following criteria managed interexperimental variability: (1) avoid using cells of passage 10 and above (LIF does not completely prevent differentiation in the later passages); (2) use sealed ampoules of dimethyl sulfoxide fresh in each replicate to avoid gradual oxidative degradation of this vehicle (Douglas, 1946) , a source of variability; and (3) evaluate a minimum of three replicates for each compound to account for background biological variability. Using the above criteria and frequency analysis, we found interexperimental repeatability improved considerably. Out of the 77 compounds evaluated, 73% presented replicates with the same teratogenic classification (Supplementary table 21) .
EST Versus MESCA Comparison
Although Fisher's exact test identified a statistically significant difference in the concordance of the training set between the EST and MESCA assays, it is important to note that only 10 compounds were completed in triplicates in the ECVAM study, but the concordance calculations were performed based on 30 treatments (counted as if the treatments were independent compounds). Also, when the training and test sets were combined, no statistical significant difference in the concordance between assays was observed (Table 10) . Furthermore, when compounds with known pharmacology to be misclassified (see Discussion section for details) were removed from the final concordance calculation, no statistical significant difference was observed between assays (Table 10) .
DISCuSSIon
We developed a simplified mouse ES cell (D3 cells) assay and a method for compound classification depending on gene transcription and cytotoxicity measurement to evaluate teratogenic potential. Using this method for the training set, we found a concordance of 72% with the reported teratogenicity of 65 compounds representing a broad spectrum of chemical structure and pharmacological "space." Our classification approach combined measurement of cytotoxicity (IC 50 ) with 
MOLECULAR EMBRYONIC STEM CELL TERATOGENICITY ASSAY 453 the transcriptional response of 12 genes to classify compounds. The transcripts selected are diverse in terms of expression and function during early embryonic development. This diversity is important because the plurality of teratogenicity mechanisms involved. Day 4 was selected based upon the expression dynamics of the selected genes and technical advantages (e.g., elimination of two time-consuming steps in the conventional EST differentiation assay). The refined EB culture method enables the possibility of automation. We found that measurement of cytotoxicity in D3 cells cultured for 3 days can both determine the optimal concentration required for the gene expression assay and provide a toxicity endpoint (IC 50 ), contributing to the classification of teratogens. This represents a significant simplification of the assay because only one cell line is required for both cytotoxicity and gene expression measurements. As a further simplification, we measured changes in gene expression at only one concentration determined from the cytotoxicity response curve (0.1 × IC 20 ). Others used single concentrations for transcriptional experiments by first completing a standard EST experiment in a dose-dependent manner and calculating an ID 50 to support the transcriptional study (van Dartel et al., 2009 (van Dartel et al., , 2010a (van Dartel et al., and b, 2011 . The use of the IC 50 as part of the classification process is supported by the reported correlation between IC 50 and ID 50 values (Marx-Stoelting et al., 2009) .
Eighteen of the training set of 65 compounds and 2 of the test set of 12 compounds (13 teratogens and 7 nonteratogens) were misclassified (compounds bolded in Tables 1 and 2 ). Four of these compounds (Table 7) are nonteratogens known to have H1 histamine receptor activity. Although there is no evidence that this compound class has teratogenic potential, the EST also misclassified a compound from this class (diphenhydramine), suggesting that this type of in vitro system may be more sensitive to this compound class . Furthermore, four compounds with GABAergic activity were misclassified (Table 8) ; three were false negatives. Alterations of GABA receptor activity have been associated with midline facial defects such as cleft palate (Asada et al., 1997; Condie et al., 1997; Ding et al., 2004; Homanics et al., 1997; Wee and Zimmerman, 1983; Zimmerman, 1985) , and the developmental pathways active in the differentiating EB may be too early to detect these types of defects. The ES cell assay (MESCA or EST) is not a complete model of all the differentiation processes involved in embryo development. Specifically, it models developmental pathways involved in early germ layer formation and cardiomyocyte differentiation. The incompleteness of the model is the most likely explanation for misclassification of certain pharmacological or structural classes, such as the histaminergic and GABAergic compounds found here. When compounds with H1 histamine and GABA pharmacology were removed from the training and test sets, total concordance improved from 72 to 78% and from 83 to 91%, respectively (Tables 5, 6 , and 9). And when MESCA was compared with the EST, no statistically significant difference was found between their concordances (Table 10 ). The streamlined rat whole embryo culture assay correctly classified 82% of H1 histamine and GABAergic compounds, therefore, it should be considered as an alternative to MESCA to screen compounds of these pharmacological classes (Zhang et al., 2012) .
Of the remaining three misclassified nonteratogens, bisphenol A has been reported to induce DNA methylation changes in utero disrupting epigenetic reprogramming mechanisms that occur early in development (Dolinoy et al., 2007) . This may explain the changes in gene expression observed in this study and its misclassification in the assay. Pergolide mesylate has been associated with a mild, transient cardiotoxicity (Kurlan et al., 1986) , which may explain the sensitivity of this in vitro system (Tables 1 and 2 ). The teratogenicity mechanism of four of these teratogens (BMS-4 [an endothelin receptor antagonist], ethanol, methanol, and lithium chloride) has been associated with disruption of neural crest migration and survival (Anthony et al., 2010; Bolon et al., 1994; Rovasio and Battiato, 1995; Spence et al., 1999) , which may be a cell lineage that has not activated its developmental program in early EBs. Penicillamine was another misclassified teratogen, where the mechanism of teratogenicity has been attributed to maternal copper deficiency and not a direct teratogenic insult to the embryo proper (Keen et al., 1983) . Furthermore, penicillamine and BMS-8 are two of three teratogens in the training set that cause only skeletal malformations in vivo. Skeletal defects may occur from alteration of early body patterning during gastrulation but could also be manifested later in development; thus, the teratogenic mechanism may not be active in the embryoid body. Thalidomide was also misclassified. Previous reports indicate that this compound is not teratogenic in the mouse (Cahen, 1966) , suggesting similar lack of sensitivity in the assay because the D3 cell line is murine.
One disadvantage of using transcriptional endpoints is the variability in gene expression observed between biological replicates. This experience has been reported by others and explained as variability in the differentiation stage of the initial cell population (van Dartel et al., 2009, 2010a and b) . This initial stage difference would lead to different expression measurements depending on where the cells are in their course of differentiation. We, however, observed similar variability in different cell lots and different cell passages. Therefore, the model was built with a large set of known in vivo teratogens and nonteratogens repeated many times at different cell passages and cell lots, and the data from these replicates were used to assess variability in the final model.
Several statistical prediction models for teratogenic classification were generated from these transcriptional data. However, most of the models that emerged from linear discriminant analysis were one-gene models, and there was concern surrounding biological significance given the vast number of mechanisms associated with teratogenic agents. Although these models were successfully cross validated, further testing of additional compounds revealed that the transcriptional response variability did not always align with RQ cutoff values, leading to incorrect classifications of interexperimental controls.
MESCA was designed as an initial screen for developmental hazard identification. The predictivity value for teratogens when removing the H1 histamine receptor and GABAergic targets (71% for the training set and 88% for the test set) ( Table 9) provides confidence in positive results and is ideal for early selection of potential lead molecules or structural series. The assay may be applied to environmental and industrial hazard identification and risk assessment although additional testing with a larger population of chemicals may be necessary for these applications.
Although the overall concordance between the EST and MESCA is very similar, we streamlined the assay, making it ideal for early evaluation of teratogenic potential based on low error rates. In the pharmaceutical setting, such assays are advantageous in the early discovery phase to guide structureactivity relationships in a cost-efficient approach using minimal amounts of compound because follow-up studies could be done later to interrogate teratogenic liability more thoroughly.
In summary, a novel MESCA was established for initial highthroughput screening of compounds for teratogenic potential, demonstrating good concordance following a stringent assay performance process.
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